drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
A CRISPR/Cas9-edited, allogeneic B7-H3 (CD276)–targeted chimeric antigen receptor (CAR) T-cell therapy administered intrapleurally; engineered T cells recognize B7-H3 on tumor cells to induce antigen-dependent T-cell activation, cytokine release, and cytotoxic killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intrapleural
drug_mechanism_of_action
CRISPR/Cas9-edited, allogeneic T cells engineered to express a B7-H3 (CD276)–specific chimeric antigen receptor. Upon binding B7-H3 on tumor cells, the CAR activates T-cell signaling, leading to cytokine release and targeted cytotoxic killing; gene edits support allogeneic use and minimize alloreactivity. Administered intrapleurally to treat pleural tumors.
drug_name
MT027
nct_id_drug_ref
NCT06726564